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The decision to eat is strongly inﬂuenced by non-homeostatic factors such as food palatability. Indeed, the rewarding
andmotivationalvalueof foodcanoverridehomeostaticsignals,leadingtoincreasedconsumptionandhence,obesity.
Ghrelin, a gut-derived orexigenic hormone, has a prominent role in homeostatic feeding. Recently, however, it has
emerged as a potent modulator of the mesolimbic dopaminergic reward pathway, suggesting a role for ghrelin in food
reward. Here, we sought to determine whether ghrelin and its receptors are important for reinforcing motivation for
natural sugar reward by examining the role of ghrelin receptor (GHS-R1A) stimulation and blockade for sucrose
progressiveratiooperantconditioning,aprocedureusedtomeasuremotivationaldrivetoobtainareward.Peripherally
and centrally administered ghrelin signiﬁcantly increased operant responding and therefore, incentive motivation for
sucrose. Utilizing the GHS-R1A antagonist JMV2959, we demonstrated that blockade of GHS-R1A signaling signiﬁ-
cantly decreased operant responding for sucrose. We further investigated ghrelin’s effects on key mesolimbic reward
nodes, the ventral tegmental area (VTA) and nucleus accumbens (NAcc), by evaluating the effects of chronic central
ghrelin treatment on the expression of genes encoding major reward neurotransmitter receptors, namely dopamine
and acetylcholine. Ghrelin treatment was associated with an increased dopamine receptor D5 and acetylcholine
receptornAChRb2geneexpressionintheVTAanddecreasedexpressionof D1,D3,D5andnAChRa3intheNAcc.Our
data indicate that ghrelin plays an important role in motivation and reinforcement for sucrose and impacts on the
expression of dopamine and acetylcholine encoding genes in the mesolimbic reward circuitry. These ﬁndings suggest
that ghrelin antagonists have therapeutic potential for the treatment of obesity and to suppress the overconsumption
of sweet food.
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INTRODUCTION
Itiswell-establishedthatthecirculatinghormoneghrelin
plays an important role in the regulation of energy
balance(Kojimaet al.1999;Nogueiras,Tschöp&Zigman
2008). Released primarily by the stomach (Dornonville
de la Cour et al. 2001), ghrelin elicits potent orexigenic
effects both in rodents and in man (Wren et al. 2000,
2001)viastimulationof itscentralnervoussystem(CNS)
receptor (Salomé et al. 2009a), the growth hormone
secretagogue receptor (GHS-R1A) (Howard et al. 1996).
Indeed, ghrelin targets hypothalamic and brain stem cir-
cuits involved in feeding and energy homeostasis
(Dickson, Leng & Robinson 1993; Bailey et al. 2000;
Hewson & Dickson 2000; Faulconbridge et al. 2003,
2008). Feeding behavior, however, is not only motivated
by the need for nutrient repletion (i.e. the need to restore
homeostasis); palatable high-fat and/or sugar foods can
motivate intake despite a state of satiety (Zheng et al.
2009). The overconsumption of palatable natural rein-
forces such as sugar is a major factor driving the current
obesity epidemic. It remains to be determined whether
thecentralghrelinsignalingsystemisimportantfornon-
homeostatic sugar consumption, thereby providing a
potentially important therapeutic target to suppress the
intake of caloric, palatable and rewarding sweet foods.
PRECLINICAL STUDY
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mesolimbic areas involved in non-homeostatic/reward
feeding (Jerlhag et al. 2007), we sought to assess the role
of ghrelin and its receptor in food motivation and goal-
directed behavior for sucrose reward. These mesolimbic
areashavelongbeenthefocusof drugaddictionresearch
as they are a major target for most drugs of abuse (Engel
1977; Koob 1992). The target mesolimbic pathway for
ghrelin includes the dopamine projection from the
ventral tegmental area (VTA) to the nucleus accumbens
(NAcc) (Jerlhag et al. 2006, 2007), a pathway conferring
reward from both addictive chemical drugs and natural
rewards, including food (Koob 1992). Interestingly, GHS-
R1Aisexpressedondopaminergicneurons(Abizaidet al.
2006),implicatingpossibledirecteffectsof ghrelinonthe
VTA dopamine system. These immunohistochemical
data are complemented by the accumulating behavioral
andelectrophysiologicalevidenceof ghrelin’seffectinthe
VTA. For example, intra-VTA administration of ghrelin
increases the activity of VTA dopamine neurons (Abizaid
et al. 2006) and increases the release of dopamine into
the NAcc (Jerlhag et al. 2007). Ghrelin also increases the
activity of the cholinergic–dopaminergic link, an impor-
tant reward pathway. Indeed, at least part of ghrelin’s
effects on dopamine seem to be mediated by the cholin-
ergic system (Jerlhag et al. 2007).
While established that ghrelin has a potent orexi-
genic effect when food is readily available, it is not yet
known whether the orexigenic effects of ghrelin can be
extended to include changing motivation and reinforc-
ing aspects of natural reinforces such as palatable sweet
food (i.e. increasing wanting, and the effort/work one is
willing to put into obtaining a sweet treat). The motiva-
tion and reward efﬁcacy of drugs of addiction can be
evaluated in the self-administration, operant condition-
ing model. Operant conditioning is a principal procedure
for the analysis of motivated behavior that assesses
acquired and voluntary behavior directed toward
obtaining a reward. By measuring the amount of work
a subject is willing to expend to obtain the reward, it
offers an objective measure of reward value (Hodos
1961). Mesolimbic regions are crucial for motivational
aspects of behavior including feeding and it is clear that
ghrelin affects neuronal activity in relevant mesolimbic
regions. What has not yet been shown is the direct
effect of ghrelin on the motivation for high-sugar food.
The primary aim of our study is to investigate whether
the central ghrelin signaling system plays a role in the
hedonic/motivational or positive reinforcing properties
of high-sugar food reward and whether suppression of
this system, utilizing a novel selective GHS-R1A antago-
nist JMV2959 (Salomé et al. 2009a), can suppress
motivation to obtain sweets. GHS-R1A antagonists
are currently being evaluated therapeutically in type 2
diabetic patients as suppression of ghrelin signaling has
beneﬁcial effects on glucose homeostasis (Sun et al.
2006), effects that would also beneﬁt from reduced
intake of sweet foods. Several lines of evidence suggest
that dopaminergic and cholinergic neurotransmission
play an important role in motivated reward behavior.
Therefore, to further characterize the effects of ghrelin
on central reward circuitry, we evaluated the impact of
ghrelin treatment on dopamine and acetylcholine recep-
tor gene expression changes in key reward nodes, the
VTA and NAcc, after ghrelin treatment.
METHODS
Animals
Adult male Sprague-Dawley rats (200–250 g, Charles
River, Germany) were housed in a 12-hour light/dark
cycle with regular chow and water available ad libitum,
except when indicated otherwise. All animal procedures
were carried out with ethical permission and in accor-
dance with the University of Gothenburg Institutional
Animal Care and Use Committee guidelines.
Surgery
For behavioral experiments targeting the CNS, a third
ventricular guide cannula (26 gauge; Plastics One,
Roanoke, VA, USA; coordinates: on the midline, 2 mm
posterior to bregma, and 5.5 mm ventral to dura mater,
with injector aimed 7.5 mm ventral to the dura) was
implanted under isoﬂurane anesthesia. Cannulae were
attached to the skull with dental acrylic and jeweler’s
screws and closed with an obturator, as described previ-
ously (Skibicka, Alhadeff & Grill 2009). Placement of the
cannula in the third ventricle was veriﬁed one week after
surgery by measurement of the sympathoadrenal-
mediated glycemic response to central injection of
5-thio-D-glucose [210 mgi n2 ml of vehicle (saline)]
(Ritter, Slusser & Stone 1981). In this placement veriﬁca-
tionprotocol,apostinjectionelevationof atleast100%of
baseline plasma glucose level was required for subject
inclusion. For the gene expression experiment, the rats
were anesthetized (60–75 mg/kg Ketalar and 0.5 mg/kg
Domitor i.p.; Pﬁzer, Sweden; Orion Co, Finland) and a
chronic intracerebroventricular (ICV) cannula (Alzet
Brain Infusion Kit II, DURECT Corp, Cupertino, CA, USA)
was inserted into the lateral ventricle using the following
coordinates: 0.6 mm posterior from bregma, 1.4 mm
lateral from midline, 2.3 ventral from skull. The cannula
was connected via a polyethylene catheter to an osmotic
minipump (Alzet Mini-Osmotic Pump Model 2002,
Durect, Cupertino, ﬂow rate, 0.5 ml/hour for 14 days)
implanted subcutaneously in the back of the animals.
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Apparatus
Operant conditioning experiments took place in eight
operant conditioning chambers designed for rats
(30.5 ¥ 24.1 ¥ 21.0 cm; Medical-Associates, Georgia,
VT, USA), which were placed in a sound-attenuated,
dimly lit cabinet. Each chamber had a metal grid ﬂoor,
two retractable levers with white light bulbs above them
andafoodpelletdispenserthatcandeliver45 mgsucrose
pellets (GlaxoSmithKline, Test Diet, Richmond, IN, USA)
to the food tray. Data collection and processing were con-
trolledbyMED-PCsoftware(Medical-Associates,Georgia,
VT, USA).
Training
Theprocedureusedforoperantconditioningwasadapted
from (la Fleur et al. 2007) and (Tracy et al. 2008). All of
the rats were subjected to a mild food restriction para-
digm during which their initial body weight was gradu-
ally reduced to 90% over a period of one week. For the
ICV-cannulated rats, the training commenced one week
afterthesurgery.Priortoplacementintheoperantboxes,
the rats were exposed to the sucrose pellets in the home
cage environment on at least two occasions. Next, the
rats learned to lever press for sucrose pellets under a ﬁxed
ratio FR1 schedule with two sessions per day. In FR1, a
single press on the active lever resulted in the delivery of
one sucrose pellet. All FR sessions lasted 30 minutes or
until the rats earned 100 pellets, whichever occurred
ﬁrst. Most of the rats achieved the 100 pellets per session
criterion after 10 to 15 sessions. Presses on the inactive
lever were recorded but had no programmed conse-
quence. FR1 schedule sessions were followed by FR3 and
FR5 (i.e. three and ﬁve presses per pellet, respectively).
Again, a minimum of 100 responses per session on the
active lever was required for the advancement to the next
schedule; most of the rats required only one to two FR3
and FR5 schedule(s) to achieve this level.The FR5 sched-
ule was followed by the progressive ratio (PR) schedule
during which the cost of a reward is progressively
increasedforeachfollowingrewardinordertodetermine
theamountof worktheratiswillingtoputintoobtaining
the reward. The response requirement increased
according to the following equation: response ratio =
[5e(0.2 ¥ infusion number)] – 5 through the following
series: 1, 2, 4, 9, 12, 15, 20, 25, 32, 40, 50, 62, 77,
95,118,145,178,219,268,328.ThePRsessionended
when the rat had failed to earn a reward within
60 minutes. The break point was deﬁned as the ﬁnal
completed ratio before the session ended. Responding
was considered stable when the number of food pellets
earned per session did not differ more than 15% for three
consecutive sessions. In most cases, responding stabilized
within ﬁve to seven sessions. PR test was carried out one
session/day. The sessions lasted, on average, 75 minutes,
althoughalltheratsstayedintheoperantboxesuntil120
minutes to allow for all the sessions to end.The rats were
subsequently transferred to home cages for a one hour
free-feeding chow intake measurement. At the end of
training and prior to testing, the rats were returned to an
ad libitum feeding schedule.
Experimental design
All of the rats received intraperitoneal (IP) or in a sepa-
rate group of rats, third ventricle (third ICV) injections
early in the light cycle (for ghrelin tests) and late in the
lightcycleforghrelinantagonistexperiments20minutes
prior to the start of operant testing. All conditions were
separated by a minimum of 48 hours and run in a coun-
terbalanced manner (each rat received all conditions on
separate testing days).
Experiment 1: impact of peripheral or central ghrelin
administration on PR operant responding for sucrose in rats.
For all the rats, lever-pressing responses were examined
after two conditions: IP treatment with saline or acylated
ratghrelin(Tocris,Bristol,UK;0.33 mg/kgbodyweightat
1 ml/kg). The selected IP ghrelin dose has been shown
previouslytoinduceafeedingresponseinrats(Wrenet al.
2000)andalsotoinduceaccumbaldopaminereleaseand
locomotor activity in mice (Jerlhag 2008). Subsequent to
operanttesting,theratswereallowedfreeaccesstochow,
and chow intake was measured after a one-hour period.
Next, in a separate group of rats, we examined responses
after targeted CNS drug delivery after three conditions as
follows: control condition with third ventricle saline,
0.5 mgo r1 . 0mg of acylated rat ghrelin (Tocris) in a 1 ml
volume.Theselecteddosesof ghrelinhaspreviouslybeen
shown to elicit feeding responses (Nakazato et al. 2001).
ForboththeICVandtheIPghrelinstudies,lever-pressing
experiments were performed in the satiated state (i.e.
when food intake would be driven by the rewarding prop-
ertiesof thefoodratherthanhomeostaticdrives).Also,in
both studies, subsequent to operant testing, the rats were
allowed free access to chow, and chow intake was mea-
sured after a one-hour period.
Experiment 2: impact of peripheral or central treatment
with a ghrelin receptor (GHS-R1A) antagonist (JMV2959)
on incentive motivation for a sucrose reward in rats. PR
operant responses were examined after three conditions
as follows: control condition with IP saline, 1 mg/kg or
3 mg/kg of JMV2959 (AEZS-123, AeternaZentaris
GmBH, Frankfurt, Germany). The JMV2959 doses were
selectedbasedonJerlhaget al.(2009)andEgeciogluet al.
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decrease conditioned place preference behavior but not
have an independent effect on locomotor activity. Subse-
quenttooperanttesting,theratswereallowedfreeaccess
to chow. To assess the effects of direct acute central
antagonist action, in a separate group of rats, operant
behavior was examined after the following three condi-
tions: control condition with third ventricle saline injec-
tion, 5 mgo r1 0mg of JMV2959 in a 1 ml volume. The
selectedICVdosesof JMV2959dosewasbasedonSalomé
et al. (2009a) in which the orexigenic action of 1 mg
ghrelin-administered ICV was blocked. Subsequent to
operant testing, the rats were allowed free access to chow
and chow intake was measured after a one-hour period
and also at 24 hours after the initial injection. Studies
with the GHS-R1A antagonist, in contrast to those per-
formed with ghrelin (see earlier), were performed on the
ratsaftera16-hourfoodrestrictionpriortotheinjections
in order to ensure high levels of endogenous circulating
ghrelin (Cummings et al. 2001).
Experiment 3: ghrelin-induced changes in expression of
dopamine- and acetylcholine-related genes in the VTA and
NAcc. Here, we determined the effects of chronic ICV
ghrelin infusion for two weeks on the expression of
selected genes involved in dopaminergic and cholinergic
transmission in two key mesolimbic reward pathway
nodes, the VTA and NAcc.The selected dopamine-related
genesweregenesencodingthedopaminereceptors(D1A,
D2, D3, D5), catechol-O-methyltransferase, tyrosine
hydroxylase (in VTA only) and monoamine oxidase A.
The acetylcholine-related genes were: nicotinic receptor
subunits (a3 a6, b2, b3).The genes we chose to evaluate
have previously been implicated in ghrelin’s effects
and/or to reward/motivation behavior (Kelley et al.
2002; Figlewicz et al. 2006; Jerlhag et al. 2006, 2007;
Sibilia et al. 2006; Dalley et al. 2007; Kuzmin et al. 2009;
Lee et al. 2009; Nimitvilai & Brodie 2010; Perello et al.
2010). A chronic ghrelin/saline infusion protocol was
used in preference to acute injection in order to increase
chancesof seeinganeffectongeneexpression;moreover,
if ghrelin is an important regulator of the reward system
in the long term, promoting overeating and obesity, its
chronic effects to alter key reward mechanisms are likely
to be of considerable importance.
Drug administration and tissue dissection
The catheter and the osmotic pump were ﬁlled with
acetylated human ghrelin (gift from Rose Pharma,
Copenhagen, Denmark) solution (8.3 mg/rat/day) or
saline vehicle solution (0.9% NaCl); this dose and length
of treatment has previously been show to affect gene
expression in the hypothalamus (Salomé et al. 2009b).
Fourteen days after implantation of the minipumps, the
rats were killed by decapitation. The brains were rapidly
removed and the VTA and the NAcc were dissected using
a brain matrix (borders of each regions were determined
based on Paxinos & Watson 1986), frozen in liquid nitro-
genandstoredat–80°Cforlaterdeterminationof mRNA
expression.
RNA isolation and mRNA expression
Individual brain samples were homogenized in Qiazol
(Qiagen, Hilden, Germany) using aTissueLyzer (Qiagen).
Total RNA was extracted using RNeasy Lipid Tissue Mini
Kit (Qiagen) or RNeasy Micro Kit (Qiagen), both with
additional DNAse treatment (Qiagen). RNA quality and
quantity were assessed by spectrophotometric measure-
ments (Nanodrop 1000, NanoDrop Technologies, Wilm-
ington, DE, USA). For cDNA synthesis, total RNA was
reversed transcribed using random hexamers (Applied
Biosystems, Sundbyberg, Sweden) and Superscript III
reverse transcriptase (Invitrogen Life Technologies,
Paisley, UK) according to the manufacturer’s description.
Recombinant RNaseout Ribonuclease Inhibitor (Invitro-
gen) was added to prevent RNase-mediated degradation.
All the cDNA-reactions were run in triplicate. Real-time
reverse transcription PCR was performed using TaqMan
Custom Array assays. They were designed with TaqMan
probe and primer sets for target genes chosen from an
on-line catalogue (Applied Biosystems). Each port on the
TaqMan Array platforms was loaded with cDNA corre-
sponding to 100 ng total RNA combined with nuclease-
free water and 50 ml TaqMan Gene Expression Master
Mix(AppliedBiosystems)toaﬁnalvolumeof 100 ml.The
TaqMan Arrays were analyzed using the 7900HT system
with a TaqMan Array Upgrade (Applied Biosystems).
Thermal cycling conditions were: 50°C for two minutes,
94.5°C for 10 minutes, followed by 40 cycles of 97°C for
30 seconds and 59.7°C for one minute.
Gene expression values were calculated based on the
DDCt method (Livak & Schmittgen 2001), where the
saline-treated group was designated the calibrator.
Brieﬂy,DCtrepresentsthethresholdcycle(Ct)of thetarget
gene minus that of the reference gene and DDCt repre-
sents the DCt of the ghrelin treated group minus that of
the calibrator. Relative quantities were determined using
the equation relative quantity = 2-DDCt. For the calibrator
sample,theequationisrelativequantity = 2-0,whichis1;
therefore, every other sample is expressed relative to this.
Glyceraldehyde-3-phosphate dehydrogenase was used as
reference gene.
Statistics
All behavioral parameters were analyzed by analysis of
variance followed by post hoc Tukey test or t-tests as
98 Karolina P. Skibicka et al.
© 2011 The Authors, Addiction Biology © 2011 Society for the Study of Addiction Addiction Biology, 17, 95–107appropriate. Statistical analyses were conducted using
Statistica software (Tulsa, OK, USA). In order to analyze
the effect of chronic central ghrelin treatment on gene
expression, t-test was used, with P-values calculated
using the DCt-values. Differences were considered signiﬁ-
cant at P < 0.05. Data are expressed as mean  SEM.
RESULTS
Experiment 1: impact of peripheral or central ghrelin
administration on PR operant responding for sucrose
in rats
Here, we employ a paradigm utilized in addiction
researchtoassesstheroleof ghrelininnaturalsweetfood
motivation and reinforcing properties of sugar. Speciﬁ-
cally, to determine the role of peripheral ghrelin admin-
istrationonsucroserewardefﬁcacy,weexaminedsucrose
self-administration in a progressive response schedule in
the rats 20 minutes after IP injection of vehicle or
ghrelin. All measures of operant behavior were signiﬁ-
cantly increased in the rats after acute peripheral ghrelin
injection: active lever pressing (P < 0.05 for all time
points), number of sugar pellets earned (P < 0.005 for all
time points) and 120 minutes break point (P < 0.005,
32.53  3.4 and 41  4.3 for vehicle and ghrelin,
respectively; Fig. 1a,b). The literature primarily supports
a central site of action for ghrelin’s orexigenic effect.
However, GHS-R1A is also expressed outside of the CNS
in sites relevant for food intake control, for example, on
the vagus nerve; therefore, it can not be ruled out that
part of the observed effects of IP ghrelin are mediated by
those peripheral receptors. Central injection of a low
volume and dose of ghrelin, however, stimulates only the
CNS GHS-R1A. Therefore, in order to determine a direct
CNS effect of ghrelin on sucrose reward efﬁcacy, we per-
formed a parallel study in which vehicle or ghrelin were
administeredbythirdventricleinjection,also20minutes
prior to the operant paradigm. Consistent with a central
site of effect hypothesis, acute ICV ghrelin injection to
rats (both 0.5 mg and 1.0 mg doses) signiﬁcantly
increased all of the aforementioned measures of operant
behavior (Fig. 2a,b). The time course of the active lever
responsesintheICVghrelinstudyrevealedthatwhilethe
effect emerged slowly during the 10- and 30-minute time
points,itreachedsigniﬁcanceat60minutes[activelever:
10 minutes F(2, 24) = 0.94, P = 0.41, 30 minutes F(2,
24) = 3.13, P = 0.06, 60 minutes F(2, 24) = 5.86,
P < 0.01, 90 minutes F(2, 24) = 6.42, P < 0.01, 120
minutes F(2, 24) = 6.03, P < 0.01; rewards earned: 10
minutes F(2, 24) = 0.26, P = 0.78, 30 minutes F(2,
24) = 2.76, P = 0.08, 60 minutes F(2, 24) = 8.31,
P < 0.005, 90 minutes F(2, 24) = 10.16, P < 0.001,
120 minutes F(2, 24) = 11.93, P < 0.001; and break
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Figure 1 Peripheral ghrelin injection increases the motivation to
obtain palatable food in a PR ratio operant conditioning model.The
number of responses on the active lever (a) and the number of
45mg sucrose rewards obtained (b) are signiﬁcantly increased by
0.33mg/kg IP ghrelin injection for a 120-minute period of operant
testing. Intake of freely available chow is also increased by IP ghrelin
injection (c). Data represent the meanSEM, n=15, *P<0.05,
**P<0.005 from vehicle
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33.15  5.52, 36  6.95 for vehicle, 0.5 mg and 1.0 mg
ghrelin, respectively)], a time course consistent with
other reports of ghrelin-induced feeding latency when
delivered by this route (Faulconbridge et al. 2003). In
bothexperiments,activityattheinactiveleverwasminor
and did not differ signiﬁcantly between the different
treatment groups (IP 4.1  1.1, 4.1  1.1 for vehicle
and ghrelin, respectively; ICV 3.9  1.1, 2.1  0.7,
3.5  1.6 for vehicle, 0.5 mg and 1.0 mg ghrelin, respec-
tively), suggesting that the treatment does not produce
unspeciﬁc non-goal directed changes in activity. Immedi-
ately after operant testing, the rats were returned to their
home cages and allowed free access to chow; the rats
injected with ghrelin, whether given peripherally
(P < 0.05) or centrally [F(2, 24) = 12.64, P < 0.001],
nearly doubled their chow intake during the ﬁrst hour as
compared with the vehicle-treated groups (Figs 1c & 2c).
In line with previous data (Faulconbridge et al. 2003)
indicating that most of the hyperphagic effect of acute
central ghrelin injection takes place within three hours
after the injection, no effect on chow intake was noted in
ourstudyatthreeto24hoursafterICVadministrationof
either dose of ghrelin [17.4  1.12, 18.42  1.34,
19.12  1.43vehicle,0.5 mgand1.0 mgghrelin,respec-
tively, F(2, 24) = 2.27, P = 0.13].
Experiment 2: impact of peripheral or central treatment
with a ghrelin receptor (GHS-R1A) antagonist
(JMV2959) on incentive motivation for sucrose
reward in rats
Next, we explored the effects of pharmacological block-
ade of GHS-R1A on sucrose reward efﬁcacy. Thus,
sucrose self-administration in a progressive response
schedule was examined in the overnight food-restricted
rats to ensure high levels of endogenous circulating
ghrelin 20 minutes after IP injection of vehicle or
1 mg/kg or 3 mg/kg of JMV2959, a GHS-R1A antago-
nist.Allof themeasuresof operantbehaviorweresigniﬁ-
cantly decreased in the rats after peripheral injection of
JMV2959 [active lever: ﬁve minutes F(2, 24) = 11.53
P < 0.0005, 120 minutes F(2, 24) = 11.27, P < 0.001;
rewards earned: ﬁve minutes F(2, 24) = 23.39
P < 0.0005, 120 minutes F(2, 24) = 9.26, P < 0.001
and break point at 120: F(2, 24) = 5.98, P < 0.01
(45.31  6.45, 42.08  5.80, 30.0  5.89 for vehicle,
1 mg/kg and 3 mg/kg JMV2959, respectively)]. Post hoc
analysis revealed that the main effect was driven by the
3 mg/kg dose (Fig. 3a,b). To determine the role of the
central ghrelin receptor in sucrose reward efﬁcacy, a
similar study was performed in which vehicle or
JMV2959 (5 mgo r1 0mg) was administered to the third
ventricle 20 minutes before the operant measurements.
All of the aforementioned measures of operant behavior
were signiﬁcantly decreased in the rats after acute third
ventricle infusion of both doses of JMV2959 (Fig. 4a,b).
The observed effect was immediate as post hoc analysis
revealed signiﬁcant differences among the treatment
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Figure 2 CNS (third ICV) ghrelin delivery increases the rewarding
value of sucrose in a PR ratio operant conditioning model. The
number of responses on the active lever (a) and the number of
45mg sucrose rewards obtained (b) are signiﬁcantly increased by
third ICV ghrelin injection for the 120-minute period of operant
testing.Short-term intake of freely available chow is also increased by
IP ghrelin injection (c). Data represent the meanSEM, n=13,
*P<0.05, **P<0.005 from vehicle, post hocTukey analysis
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chamber that were maintained throughout the testing
period [active lever: 10 minutes F(2, 24) = 10.16,
P < 0.0005, 30 minutes F(2, 24) = 11.48, P < 0.0005,
60 minutes F(2, 24) = 9.11, P < 0.001, 90 minutes F(2,
24) = 8.30, P < 0.001, 120 minutes F(2, 24) = 4.95,
P < 0.05; rewards earned: 10 minutes F(2, 24) = 21.23,
P < 0.0001, 30 minutes F(2, 24) = 25.08, P < 0.0001,
60 minutes F(2, 24) = 19.24, P < 0.0001, 90 minutes
F(2, 24) = 20.04, P < 0.0001, 120 minutes F(2,
24) = 5.44, P < 0.01; and break point: F(2, 24) = 3.78,
P < 0.05(51.4  8.58,38.13  5.07,33.67  5.21for
vehicle, 5 mg and 10 mg JMV2959, respectively)].
As expected (Hodos 1961; Jewett et al. 1995), in all
the treatment groups, including both IP and ICV admin-
istration routes, the effect of food deprivation on the
operant response for sucrose was evident (Figs 3a & 4a)
and contrasts with that observed in the satiated state
(Figs 1a & 2a). Activity on the inactive lever was
minor (IP 9.6  3.0, 6.8  2.2, 5.6  1.9 for vehicle
and 1 mg/kg or 3 mg/kg JMV2959; ICV 6.4  1.3,
4.6  1.3, 4.4  1.7 for vehicle, 5 mg and 10 mgo f
JMV2959, respectively) and whether administered
peripherally or centrally, JMV2959 did not have any sig-
niﬁcant effect on that activity (this activity did not differ
signiﬁcantly between the different treatment groups). For
the ICV study, immediately after the operant testing, the
rats were returned to their home cages and allowed
free access to chow; interestingly, no effect on chow
intake was noted at either the one-hour (Fig. 4c) or
24-hour time point (data not shown).This could indicate
that while ghrelin signaling is required for the
deprivation-inducedfoodmotivation,itisnotessentialfor
the free feeding induced by 16 hours food deprivation
likely because of other redundant mechanisms activated
during a deprivation period. All of the free feeding mea-
surements took place 140 minutes postinjection of the
drug and so we can not exclude that the lack of effect is
partially due to wash out of the drug.
Experiment 3: ghrelin-induced changes in expression of
dopamine- and acetylcholine-related genes in the VTA
and NAcc
In the present study, we also explored whether the
dopamine- and acetylcholine-related genes are altered by
ghrelin in key mesolimbic nodes, the VTA and NAcc, by
examining the effects of chronic central ghrelin treat-
ment on the expression of selected dopamine receptors
and enzymes involved in dopamine production and
metabolism,inaparadigmalreadyestablishedtoproduce
ghrelin associated changes in gene expression in the
hypothalamus (Salomé et al. 2009b). In the VTA dopam-
ine receptor D5 and nicotinic acetylcholine receptor
(nAChRb2) had an increased mRNA expression in the
ghrelin-treated rats compared with the saline-treated
group (Fig. 5a). In the NAcc, there was a decreased
mRNAexpressionof thegenesencodingdopaminerecep-
tors D1A, D3 and D5 and also the nicotinic acetylcholine
receptor nAChRa3 in the ghrelin-treated rats compared
with the saline-treated group (Fig. 5b).
DISCUSSION
Here, we reveal a role for the central ghrelin signaling
system in the modulation of incentive motivation and
reinforcing properties of sucrose reward and indicate an
impact of chronic central ghrelin treatment on gene
expression of dopaminergic and cholinergic receptors in
key mesolimbic reward nodes. The results demonstrate
that both central and peripheral delivery of ghrelin sig-
niﬁcantly increases the amount of work an animal is
willing to do to obtain sucrose reward. Furthermore,
systemic or central blockade of the ghrelin receptor sup-
pressed operant responding for sucrose. Thus, we may
infer that endogenous ghrelin signaling is of importance
for the incentive motivation for a sucrose reward. Our
ﬁndingsareinlinewiththehypothesisthatanimportant
role of the central ghrelin signaling system is to increase
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Figure 3 Peripheral delivery of a ghrelin
receptor antagonist, JMV2959. decreases
the motivation to obtain palatable food in a
PR ratio operant conditioning model.The
number of responses on the active lever
(a) and the number of 45mg sucrose
rewards obtained (b) are signiﬁcantly
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food restriction increases the rewarding value of sucrose
(Hodos 1961; Jewett et al. 1995) and that ghrelin levels
are elevated during short-term food restriction (Gualillo
et al. 2002), it is possible that during a state of food
restriction/deprivation, ghrelin is one of the contributing
factors that increases the rewarding value of food/food
motivation. Indeed, peripheral ghrelin exposure
increased operant behavior to levels similar to those
observed in food-deprived rats, and conversely, blockade
of ghrelin signaling decreased operant behavior to levels
noted in the non-deprived rats.
Itnowseemsclearthatproblematicallyincreasedfood
intake likely reﬂects a dysregulation of the central
mechanisms of food reward, involving both hedonic
and motivational aspects. As free feeding and reward-
motivatedfeedingappeartobetwoseparablephenomena
with differential controlling neuroanatomical substrates
(Salamone et al. 1991), it is important to examine both
whenassessingaroleof agentsinvolvedinfeedingbehav-
ior. Ghrelin’s potent orexigenic effects have largely been
studied in free feeding access models in which it would be
difﬁcult to distinguish between its role in nutrient reple-
tion versus reward-motivated feeding. In the present
study, we found that GHS-R1A ligands interfere with the
motivation for sucrose reward, using an experimental
model that has been used in other contexts to show
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Figure 5 Dopamine and acetylcholine associated gene expression
inVTA (a) and NAcc (b) after chronic ICV ghrelin or vehicle treat-
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102 Karolina P. Skibicka et al.
© 2011 The Authors, Addiction Biology © 2011 Society for the Study of Addiction Addiction Biology, 17, 95–107wanting and motivation for addictive drugs of abuse. An
increaseinmotivatedbehavioriscommontobothchemi-
cal drug addiction and caloric restriction and likely
involves overlapping neurobiological mechanisms. In the
presentstudy,wealsodetectedaghrelin-inducedincrease
in free feeding of normal chow food in the same animals
that expended signiﬁcantly more work for food in the
operant chamber. Therefore, our data, taken together
with earlier reports of ghrelin effects in free feeding
models (Wren et al. 2000), indicate that ghrelin has the
ability to modulate both free feeding as well as feeding
motivation.
Given that the ghrelin receptor GHS-R1A is present in
key hypothalamic, hindbrain and mesolimbic areas
involved in energy balance and reward (Zigman et al.
2006)andthatcentralventricularinjectionof GHS-R1A
ligands likely gain widespread access to these CNS areas,
there could be several relevant neuroanatomical sub-
strates for the sucrose reward motivation effect of ghrelin
shown here. It seems likely that ghrelin acts directly on
key mesolimbic areas as ghrelin activates VTA dopamine
neurons(Abizaidet al.2006)anddirectadministrationof
ghrelin to the VTA increases accumbal dopamine release
(Jerlhag et al. 2007). Consistent with this, we have previ-
ouslyreportedeffectsof intra-VTAghrelintoincreasethe
consumption of rewarding/palatable food in free choice
feeding paradigms and also that lesions of the VTA blunt
ghrelin-induced exploratory behavior of palatable food
(Egecioglu et al. 2010). The NAcc may also be a direct
target for ghrelin in modulating motivational aspects of
food intake; when injected directly into this area, ghrelin
induces a feeding response (Naleid et al. 2005), although
the presence of GHS-R1A in this area in rodents was not
described by other investigators (Zigman et al. 2006) and
hence, requires further clariﬁcation.
Consistently, with its essential role in motivated
behaviors, several genes within the dopamine system
were altered by central ghrelin treatment. These data
raise the possibility that regulation of dopamine recep-
tor expression is a long-term mechanism via which
ghrelin impacts on the reward-related function and sig-
naling. Evaluation of dopamine receptors is not only
important at the site of release such as the NAcc but
also in the VTA as because of dendritic dopamine
release (Cragg & Greenﬁeld 1997), it is likely that it acts
locally to inﬂuence reward motivated behaviors. Here,
we found an increased expression of D5 in the VTA after
ghrelin treatment. Dopamine D5 receptors are present
on the cell bodies of dopaminergic VTA neurons (Ciliax
et al. 2000) and their activity is required to restore the
VTA dopamine neuron activity after a period of desen-
sitization (Nimitvilai & Brodie 2010). In the NAcc, we
noted a decreased expression of D1. In fact, reduced
expression of this receptor has been recently shown in
the NAcc of obesity prone but not obesity-resistant rats
on high fat diet indicating its potential role in NAcc in
obesity and overconsumption (Alsio et al. 2010). Also,
the expression of genes encoding D3 was reduced by
ghrelin, a ﬁnding of particular interest given the
decreased availability of D2/D3 receptors in both rat
and human drug users correlates with increased impul-
sivity (Dalley et al. 2007; Lee et al. 2009). Interestingly,
we did not see any signiﬁcant changes in the enzymes
involved in dopamine synthesis or production.
The important role of the acetylcholine system for
drug and food rewards is well-documented; here, we
showthatghrelintreatmentwasassociatedwithchanges
in expression of genes encoding several acetylcholine
nicotinic receptors subunits, providing another route by
which ghrelin can potentially alter reward function.
Ghrelin can regulate VTA dopaminergic neurons indi-
rectly via its action on the cholinergic neurons in the
laterodorsal tegmental area (LDTg), an area rich in GHS-
R1A, which is important for alcohol reward involving a
cholinergic projection to the VTA dopamine system. In
fact,previously,weshowedthatbilateralghrelininjection
into the LDTg in mice stimulates dopamine release in a
cholinergic-dependent manner (Jerlhag et al. 2007,
2008) and increases consumption of alcohol in a free
choice (alcohol/water) drinking paradigm (Jerlhag et al.
2009). Indeed, recent studies have implicated the
cholinergic–dopamineric reward link in food reward
(Dickson et al. 2010). Another interesting possibility is
that ghrelin can enhance cholinergic signaling in the
VTA via upregulation of cholinergic receptors. Indeed,
our current gene expression data seems to support that
mechanism as VTA nAChRb2 mRNA levels were
increased in the ghrelin-treated rats.
The function of NAcc cholinergic neurons and acetyl-
choline in the NAcc, on the other hand, have been more
controversial with some reports indicating a role of ace-
tylcholine in increasing reward-oriented behavior (Pratt
& Kelley 2005; Pratt & Blackstone 2009) but others indi-
cating that Ach in NAcc may act to inhibit feeding and
play a role in satiety mechanism (Helm et al. 2003;
Hoebel et al. 2007). Indeed, our results seem to be consis-
tent with the latter as ghrelin treatment was associated
with a decreased expression of one of the nicotinic recep-
tor subunits, the nAChRa3. It is important to note that
the gene expression studies, while very valuable in indi-
cating potential downstream targets of ghrelin, only
suggest the type of relationship (upregulation or down-
regulation) needed for expression of the orexigenic-/
reward-oriented response but do not deﬁne it as it would
be difﬁcult to dissociate direct from compensatory
changes. Therefore, our gene expression studies indicate
a connection and provide a platform for future genetic
and pharmacological studies determining the role of
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motivated feeding.
Although hypothalamic and brainstem areas most
likely contribute to homeostatic feeding, we can not
exclude an indirect role for hypothalamic and/or brain-
stem afferent systems in ghrelin-induced food reward
motivation. Indeed, the orexinergic neurons project from
the lateral hypothalamus to mesolimbic reward circuitry
includingtheVTAandNAcc(Toshinaiet al.2003;Harris
et al. 2005; Perello et al. 2010). The neuropeptide Y
(NPY)/AgRP neurons of the arcuate nucleus, another
target for GHS-R1A ligands (Dickson & Luckman 1997;
Keen-Rhinehart & Bartness 2007a,b), may also play an
important role. NPY has been shown to increase reward
efﬁcacy of chow as well as sucrose (Brown, Fletcher &
Coscina 1998), whereas AgRP appears to increase
reward efﬁcacy of high-fat food only (Tracy et al. 2008).
Ghrelin appears to have a role in both sucrose reward
(present study) and in high-fat reward (Perello et al.
2010); however, the relative importance of the NPY/
AgRP neurons for these effects of ghrelin remains to be
elucidated. In summary, ghrelin has food motivational
properties spanning across nutritional components and
most likely affects several brain areas to synchronize a
coordinated behavioral response to promote feeding.
Although ghrelin transport into the brain is limited
(Banks et al. 2002), peripheral ghrelin appears to access
and target areas such as the hippocampus (Diano et al.
2006) and VTA (Jerlhag 2008). Although there remains
some debate over the relevance of the vagus nerve as an
indirect route for ghrelin’s central effects (Dornonville de
la Cour et al. 2005; Date et al. 2002; Arnold et al. 2006),
adirectactionwithintheCNSseemslikelyastheeffectsof
peripheral ghrelin on food intake can be suppressed by
intra-VTA administration of ghrelin antagonists (Abizaid
et al.2006).Ghrelinisproducedwithinthebrain(Cowley
et al. 2003), although it remains to be determined how
this is regulated and whether brain-derived ghrelin pro-
vides an important centrally generated signal for food
intake and for the motivation to eat.Taken together with
the fact that the ghrelin receptor GHS-R1A is constitu-
tively active (i.e. has activity in the absence of ghrelin
ligand) (Holst et al. 2003), the question arises as to
whether circulating ghrelin provides a physiologically
relevant gut–brain signal for incentive motivation for
food reward. The results of the present study, showing
similar effects on sucrose reward work can be obtained
via central and peripheral administration of GHS-R1A
ligands,couldindicatethatbothcentrallyreleasedaswell
asperipherallyreleasedghrelincanpotentiallyaffectfood
motivation.
In conclusion, our new data provide new evidence
that ghrelin signaling is important for the motivation to
obtain sucrose reward and impact on dopaminergic and
cholinergic gene expression in mesolimbic reward
pathway. Our ﬁndings inspire important questions
regarding the role of the endogenous ghrelin in deter-
mining the incentive value for natural rewards such as
sugar, in normal appetitive behavior and in the patho-
physiology of eating disorders and obesity. Although sig-
niﬁcant work remains to relate causally the molecular
changes in the dopamine and acetylcholine system to
impact of ghrelin on reward, our data potentially
indicate a novel mechanism by which ghrelin impacts
on the reward behavior. Understanding ghrelin’s role
in reward processes is important for the understanding
of the overlapping neurobiology of eating disorders
and chemical drug addiction and provides a potential
avenue for understanding the etiology of these diseases
and for the development of novel therapies. Finally, the
possibility to suppress problematic overeating of palat-
able sweet foods using GHS-R1A antagonists may have
clinical and therapeutic relevance for the emerging ben-
eﬁcial effects of such compounds for blood glucose
control (Sun et al. 2006) in type 2 diabetic patients
(Esler et al. 2007).
Acknowledgements
Research supported by the Swedish Research Council for
Medicine (VR 2006-5663; 2009-S266), European
Union 7th Framework (FP7-HEALTH-2009-241592;
FP7-KBBE-2009-3-245009), ALF Göteborg (SU7601),
the Swedish Institute and the Swedish Foundation for
Strategic Research to Sahlgrenska Center for Cardiovas-
cular and Metabolic Research (A305-188). We would
also like to thank Dr. Daniel Perrissoud (AeternaZenta-
ris, GmBH, Germany) for providing the GHS-R1A
antagonist JMV2959 and Anders Friberg for assistance
with submission.
Authors Contribution
KPS initiated, designed, performed and analyzed all
behavioral studies. CH performed and analyzed all gene
expression studies. EE contributed to initiation of the
study. SLD was senior author, and provided supervision
and ﬁnancial support for all studies.The manuscript was
created by KPS and SLD, all authors contributed to the
ﬁnal text.
References
Abizaid A, Liu ZW, Andrews ZB, Shanabrough M, Borok E,
Elsworth JD, Roth RH, Sleeman MW, Picciotto MR, Tschop
MH, Gao XB, Horvath TL (2006) Ghrelin modulates the activ-
ity and synaptic input organization of midbrain dopamine
neurons while promoting appetite. J Clin Invest 116:3229–
3239.
104 Karolina P. Skibicka et al.
© 2011 The Authors, Addiction Biology © 2011 Society for the Study of Addiction Addiction Biology, 17, 95–107Alsio J, Olszewski PK, Norback AH, Gunnarsson ZE, Levine AS,
Pickering C, Schioth HB (2010) Dopamine D1 receptor gene
expression decreases in the nucleus accumbens upon long-
term exposure to palatable food and differs depending on diet-
induced obesity phenotype in rats. Neuroscience 171:779–
787.
Arnold M, Mura A, Langhans W, Geary N (2006) Gut vagal
afferents are not necessary for the eating-stimulatory effect of
intraperitoneally injected Ghrelin in the rat. J Neurosci
26:11052–11060.
Bailey ART, Von Englehardt N, Leng G, Smith RG, Dickson SL
(2000) Growth hormone secretagogue activation of the
arcuate nucleus and brainstem occurs via a non-
noradrenergic pathway. J Neuroendocrinol 12:191–197.
Banks WA, Tschop M, Robinson SM, Heiman ML (2002) Extent
and direction of ghrelin transport across the blood–brain
barrier is determined by its unique primary structure. J Phar-
macol Exp Ther 302:822–827.
Brown CM, Fletcher PJ, Coscina DV (1998) Neuropeptide
Y-induced operant responding for sucrose is not mediated by
dopamine. Peptides 19:1667–1673.
Ciliax BJ, Nash N, Heilman C, Sunahara R, Hartney A, Tiberi M,
Rye DB, Caron MG, Niznik HB, Levey AI (2000) Dopamine
D(5) receptor immunolocalization in rat and monkey brain.
Synapse 37:125–145.
Cowley MA, Smith RG, Diano S, Tschop M, Pronchuk N, Grove
KL, Strasburger CJ, Bidlingmaier M, Esterman M, Heiman ML,
Garcia-Segura LM, Nillni EA, Mendez P, Low MJ, Sotonyi P,
FriedmanJM,LiuHY,PintoS,ColmersWF,ConeRD,Horvath
TL (2003) The distribution and mechanism of action of
ghrelin in the CNS demonstrates a novel hypothalamic circuit
regulating energy homeostasis. Neuron 37:649–661.
Cragg SJ, Greenﬁeld SA (1997) Differential autoreceptor control
of somatodendritic and axon terminal dopamine release in
substantianigra,ventraltegmentalarea,andstriatum.JNeu-
rosci 17:5738–5746.
Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE,
Weigle DS (2001) A preprandial rise in plasma ghrelin levels
suggests a role in meal initiation in humans. Diabetes
50:1714–1719.
Dalley JW, Fryer TD, Brichard L, Robinson ES, Theobald DE,
LaaneK,PenaY,MurphyER,ShahY,ProbstK,AbakumovaI,
Aigbirhio FI, Richards HK, Hong Y, Baron JC, Everitt BJ,
Robbins TW (2007) Nucleus accumbens D2/3 receptors
predict trait impulsivity and cocaine reinforcement. Science
315:1267–1270.
Date Y, Murakami N, Toshinai K, Matsukura S, Niijima A,
Matsuo H, Kangawa K, Nakazato M (2002) The role of the
gastric afferent vagal nerve in ghrelin-induced feeding and
growth hormone secretion in rats. Gastroenterology
123:1120–1128.
Diano S, Farr SA, Benoit SC, McNay EC, da Silva I, Horvath B,
Gaskin FS, Nonaka N, Jaeger LB, Banks WA, Morley JE, Pinto
S, Sherwin RS, Xu L, Yamada KA, Sleeman MW, Tschop MH,
Horvath TL (2006) Ghrelin controls hippocampal spine
synapse density and memory performance. Nature Neuro-
science 9:381–388.
Dickson SL, Hrabovszky E, Hansson C, Jerlhag E, Alvarez-Crespo
M, Skibicka KP, Molnar CS, Liposits Z, Engel JA, Egecioglu E
(2010) Blockade of central nicotine acetylcholine receptor
signaling attenuate ghrelin-induced food intake in rodents.
Neuroscience 171:1180–1186.
Dickson SL, Leng G, Robinson ICAF (1993) Systemic adminis-
tration of growth hormone-releasing peptide activates
hypothalamic arcuate neurons. Neuroscience 53:303–
306.
Dickson SL, Luckman SM (1997) Induction of c-fos messenger
ribonucleicacidinneuropeptideYandgrowthhormone(GH)-
releasing factor neurons in the rat arcuate nucleus following
systemic injection of the GH secretagogue, GH-releasing
peptide-6. Endocrinology 138:771–777.
Dornonville de la Cour CD, Björkqvist M, Sandvik AK, Bakke I,
Zhao CM, Chen D, Håkanson R (2001) A-like cells in the rat
stomach contain ghrelin and do not operate under gastrin
control. Regul Pept 99:141–150.
Dornonville de la Cour CD, Lindqvist A, Egecioglu E, Tung YCL,
Surve V, Ohlsson C, Jansson JO, Erlanson-Albertsson C,
Dickson SL, Hakanson R (2005) Ghrelin treatment reverses
the reduction in weight gain and body fat in gastrectomised
mice. Gut 54:907–913.
Egecioglu E, Jerlhag E, Skibicka S, Salomé N, Haage D, Bohlooly
YM, Andersson D, Bjursell M, Perrissoud D, Engel JA, Dickson
SL (2010) Ghrelin increases intake of palatable food in
rodents. Addict Biol 15:304–311.
Engel JA (1977) Neurochemical aspects of the europhoria
induced by dependence-producing drugs. Recent Advances
in the Study of Alcoholism (Excerpta Medica Inter-
national Congress Series), pp. 16–22. Amsterdam: Excerta
Medica.
Esler WP, Rudolph J, Claus TH, Tang WF, Barucci N, Brown SE,
BullockW,DalyM,DeCarrL,LiYX,MilardoL,MolstadD,Zhu
J, Gardell SJ, Livingston JN, Sweet LJ (2007) Small-molecule
ghrelin receptor antagonists improve glucose tolerance, sup-
press appetite, and promote weight loss. Endocrinology
148:5175–5185.
Faulconbridge LF, Cummings DE, Kaplan JM, Grill HJ (2003)
Hyperphagic effects of brainstem ghrelin administration. Dia-
betes 52:2260–2265.
Faulconbridge LF, Grill HJ, Kaplan JM, Daniels D (2008) Caudal
brainstem delivery of ghrelin induces fos expression in the-
nucleusof thesolitarytract,butnotinthearcuateorparaven-
tricular nuclei of the hypothalamus. Brain Res 1218:
151–157.
Figlewicz DP, Bennett JL, Naleid AM, Davis C, Grimm JW
(2006) Intraventricular insulin and leptin decrease sucrose
self-administration in rats. Physiol Behav 89:611–616.
Gualillo O, Caminos JE, Nogueiras R, Seoane LM, Arvat E, Ghigo
E,CasanuevaFF,DieguezC(2002)Effectof foodrestrictionon
ghrelin in normal-cycling female rats and in pregnancy. Obes
Res 10:682–687.
Harris GC, Wimmer M, Aston-Jones G (2005) A role for lateral
hypothalamic orexin neurons in reward seeking. Nature
437:556–559.
Helm KA, Rada P, Hoebel BG (2003) Cholecystokinin combined
withserotonininthehypothalamuslimitsaccumbensdopam-
ine release while increasing acetylcholine: a possible satiation
mechanism. Brain Res 963:290–297.
Hewson AK, Dickson SL (2000) Systemic administration of
ghrelin induces Fos and Egr-1 proteins in the hypothalamic
arcuate nucleus of fasted and fed rats. J Neuroendocrinol
12:1047–1049.
Hodos W (1961) Progressive ratio as a measure of reward
strength. Science 134:943–944.
Hoebel BG, Avena NM, Rada P (2007) Accumbens dopamine-
acetylcholine balance in approach and avoidance. Curr Opin
Pharmacol 7:617–627.
Holst B, Cygankiewicz A, Jensen TH, Ankersen M, Schwartz
TW (2003) High constitutive signaling of the ghrelin
Role of ghrelin in food reward 105
© 2011 The Authors, Addiction Biology © 2011 Society for the Study of Addiction Addiction Biology, 17, 95–107receptor––identiﬁcation of a potent inverse agonist. Mol
Endocrinol 17:2201–2210.
Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA,
Rosenblum CI, Hamelin M, Hreniuk DL, Palyha OC, Anderson
J, Paress PS, Diaz C, Chou M, Liu KK, McKee KK, Pong SS,
Chaung LY, Elbrecht A, Dashkevicz M, Heavens R, Rigby M,
Sirinathsinghji DJS, Dean DC, Melillo DG, Patchett AA,
NargundR,GrifﬁnPR,DeMartinoJA,GuptaSK,SchaefferJM,
Smith RG, VanderPloeg LHT (1996) A receptor in pituitary
and hypothalamus that functions in growth hormone release.
Science 273:974–977.
Jerlhag E (2008) Systemic administration of ghrelin induces
conditioned place preference and stimulates accumbal
dopamine. Addict Biol 13:358–363.
Jerlhag E, Egecioglu E, Dickson SL, Andersson M, Svensson L,
Engel JA (2006) Ghrelin stimulates locomotor activity and
accumbal dopamine-overﬂow via central cholinergic systems
in mice: implications for its involvement in brain reward.
Addict Biol 11:45–54.
Jerlhag E, Egecioglu E, Dickson SL, Douhan A, Svensson L, Engel
JA (2007) Ghrelin administration into tegmental areas stimu-
lates locomotor activity and increases extracellular concen-
tration of dopamine in the nucleus accumbens. Addict Biol
12:6–16.
Jerlhag E, Egecioglu E, Dickson SL, Svensson L, Engel JA (2008)
Alpha-conotoxin MII-sensitive nicotinic acetylcholine recep-
tors are involved in mediating the ghrelin-induced locomotor
stimulation and dopamine overﬂow in nucleus accumbens.
Eur Neuropsychopharmacol 18:508–518.
Jerlhag E, Egecioglu E, Landgren S, Salomé N, Heilig M,
Moechars D, Datta R, Perrissoud D, Dickson SL, Engel JA
(2009) Requirement of central ghrelin signaling for
alcohol reward. Proc Natl Acad SciUSA106:11318–
11323.
Jewett DC, Cleary J, Levine AS, Schaal DW, Thompson T (1995)
Effects of neuropeptide Y, insulin, 2-deoxyglucose, and food
deprivation on food-motivated behavior. Psychopharmacol-
ogy 120:267–271.
Keen-RhinehartE,BartnessTJ(2007a)MTIIattenuatesghrelin-
and food deprivation-induced increases in food hoarding and
food intake. Horm Behav 52:612–620.
Keen-Rhinehart E, Bartness TJ (2007b) NPY Y1 receptor is
involved in ghrelin- and fasting-induced increases in foraging,
food hoarding, and food intake. Am J Physiol Regul Integr
Comp Physiol 292:R1728–1737.
KelleyAE,BakshiVP,HaberSN,SteiningerTL,WillMJ,ZhangM
(2002)Opioidmodulationof tastehedonicswithintheventral
striatum. Physiol Behav 76:365–377.
KojimaM,HosodaH,DateY,NakazatoM,MatsuoH,Kangawa K
(1999) Ghrelin is a growth-hormone-releasing acylated
peptide from stomach. Nature 402:656–660.
Koob GF (1992) Drugs of abuse––anatomy, pharmacology and
function of reward pathways. Trends Pharmacol Sci 13:177–
184.
Kuzmin A, Jerlhag E, Liljequist S, Engel J (2009) Effects of
subunit selective nACh receptors on operant ethanol
self-administration and relapse-like ethanol-drinking behav-
ior. Psychopharmacology 203:99–108.
la Fleur SE, Vanderschuren LJ, Luijendijk MC, Kloeze BM, Ties-
jema B, Adan RA (2007) A reciprocal interaction between
food-motivated behavior and diet-induced obesity. Int J Obes
31:1286–1294.
Lee B, London ED, Poldrack RA, Farahi J, Nacca A, Monterosso
JR,MumfordJA,BokariusAV,DahlbomM,MukherjeeJ,Bilder
RM, Brody AL, Mandelkern MA (2009) Striatal dopamine
d2/d3 receptor availability is reduced in methamphetamine
dependence and is linked to impulsivity. J Neurosci
29:14734–14740.
LivakKJ,SchmittgenTD(2001)Analysisof relativegeneexpres-
sion data using real-time quantitative PCR and the 2(-delta
delta C(T)) method. Methods 25:402–408.
Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H,
Kangawa K, Matsukura S (2001) A role for ghrelin in the
central regulation of feeding. Nature 409:194–198.
Naleid AM, Grace MK, Cummings DE, Levine AS (2005) Ghrelin
induces feeding in the mesolimbic reward pathway between
the ventral tegmental area and the nucleus accumbens. Pep-
tides 26:2274–2279.
Nimitvilai S, Brodie MS (2010) Reversal of prolonged dopamine
inhibition of dopaminergic neurons of the ventral tegmental
area. J Pharmacol Exp Ther 333:555–563.
Nogueiras R, Tschöp MH, Zigman JM (2008) Central nervous
system regulation of energy metabolism––ghrelin versus
leptin. Ann NY Acad Sci 1126:14–19.
Paxinos G, Watson C (1986) The Rat Brain in Stereotaxic Coor-
dinates. NewYork: Academic Press, NewYork.
Perello M, Sakata I, Birnbaum S, Chuang JC, Osborne-Lawrence
S, Rovinsky SA, Woloszyn J, Yanagisawa M, Lutter M, Zigman
JM (2010) Ghrelin increases the rewarding value of high-fat
diet in an orexin-dependent manner. Biol Psychiatry 67:880–
886.
Pratt WE, Blackstone K (2009) Nucleus accumbens acetylcho-
line and food intake: decreased muscarinic tone reduces
feeding but not food-seeking. Behav Brain Res 198:252–257.
Pratt WE, Kelley AE (2005) Striatal muscarinic receptor antago-
nism reduces 24-h food intake in association with decreased
preproenkephalin gene expression. Eur J Neurosci 22:3229–
3240.
RitterRC,SlusserPG,StoneS(1981)Glucoreceptorscontrolling
feeding and blood–glucose––location in the hindbrain.
Science 213:451–453.
Salamone JD, Steinpreis RE, McCullough LD, Smith P, Grebel D,
MahanK(1991)Haloperidolandnucleusaccumbensdopam-
ine depletion suppress lever pressing for food but increase free
food consumption in a novel food choice procedure. Psychop-
harmacology 104:515–521.
SaloméN,HaageD,PerrissoudD,MoulinA,DemangeL,Egecio-
glu E, Fehrentz JA, Martinez J, Dickson SL (2009a) Anorexi-
genic and electrophysiological actions of novel ghrelin
receptor (GHS-R1A) antagonists in rats. Eur J Pharmacol
612:167–173.
Salomé N, Hansson C, Taube M, Gustafsson-Ericson L, Egecioglu
E, Karlsson-Lindahl L, Fehrentz JA, Martinez J, Perrissoud D,
Dickson SL (2009b) On the central mechanism underlying
ghrelin’s chronic pro-obesity effects in rats: new insights from
studies exploiting a potent ghrelin receptor antagonist. J Neu-
roendocrinol 21:777–785.
Sibilia V, Lattuada N, Rapetti D, Pagani F, Vincenza D, Bulgarelli
I, Locatelli V, Guidobono F, Netti C (2006) Ghrelin inhibits
inﬂammatory pain in rats: involvement of the opioid system.
Neuropharmacology 51:497–505.
Skibicka KP, Alhadeff AL, Grill HJ (2009) Hindbrain
cocaine- and amphetamine-regulated transcript induces
hypothermia mediated by GLP-1 receptors. J Neurosci
29:6973–6981.
Sun Y, Asnicar M, Saha PK, Chan L, Smith RG (2006) Ablation
of ghrelin improves the diabetic but not obese phenotype of
ob/ob mice. Cell Metab 3:379–386.
106 Karolina P. Skibicka et al.
© 2011 The Authors, Addiction Biology © 2011 Society for the Study of Addiction Addiction Biology, 17, 95–107ToshinaiK,DateY,MurakamiN,ShimadaM,MondalMS,Shim-
bara T, Guan JL, Wang QP, Funahashi H, Sakurai T, Shioda S,
Matsukura S, Kangawa K, Nakazato M (2003) Ghrelin-
inducedfoodintakeismediatedviatheorexinpathway.Endo-
crinology 144:1506–1512.
Tracy AL, Clegg DJ, Johnson JD, Davidson TL, Benoit SC (2008)
The melanocortin antagonist AgRP for a fat, but not a (83–
132)increasesappetitiverespondingcarbohydrate,reinforcer.
Pharmacol Biochem Behav 89:263–271.
Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG,
Dhillo WS, Ghatei MA, Bloom SR (2001) Ghrelin enhances
appetite and increases food intake in humans. J Clin Endo-
crinol Metab 86:5992–5995.
Wren AM, Small CJ, Ward HL, Murphy KG, Dakin CL, Taheri S,
KennedyAR,RobertsGH,MorganDGA,GhateiMA,BloomSR
(2000) The novel hypothalamic peptide ghrelin stimulates
food intake and growth hormone secretion. Endocrinology
141:4325–4328.
Zheng H, Lenard NR, Shin AC, Berthoud HR (2009) Appetite
control and energy balance regulation in the modern world:
reward-driven brain overrides repletion signals. Int J Obes 33
(Suppl. 2):S8–S13.
Zigman JM, Jones JE, Lee CE, Saper CB, Elmquist JK (2006)
Expressionof ghrelinreceptormRNAintheratandthemouse
brain. J Comp Neurol 494:528–548.
Role of ghrelin in food reward 107
© 2011 The Authors, Addiction Biology © 2011 Society for the Study of Addiction Addiction Biology, 17, 95–107